NASDAQ: INDPIndaptus Therapeutics Inc Stock
$1.25-0.08 (-6.02%)
Updated Aug 6, 2026
INDP Price
$1.25
Fair Value Price
N/A
Market Cap
$141.55M
52 Week Low
$0.92
52 Week High
$8.69
P/E
-0.08x
P/B
113.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.75
Operating Cash Flow
-$17M
Beta
1.25
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
INDP Overview
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INDP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important INDP news, forecast changes, insider trades & much more!
INDP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INDP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INDP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INDP is poor value based on its book value relative to its share price (113.44x), compared to the US Biotechnology industry average (5.72x)
P/B vs Industry Valuation
INDP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INDP due diligence checks available for Premium users.
Valuation
INDP fair value
Fair Value of INDP stock based on Discounted Cash Flow (DCF)
Price
$1.25
Fair Value
$8.81
Undervalued by
85.81%
INDP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INDP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
14.46x
Market
14.05x
INDP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
113.44x
Industry
5.72x
INDP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INDP's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
INDP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.2M
Liabilities
$933.0k
Debt to equity
0.75
INDP's short-term assets ($2.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INDP's short-term assets ($2.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INDP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INDP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.0M
Investing
$0.0
Financing
$0.0
INDP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INDP vs Biotech Stocks
Indaptus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.